Last reviewed · How we verify
(S)-Remoxipride — Competitive Intelligence Brief
marketed
remoxipride
D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
(S)-Remoxipride (REMOXIPRIDE).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| (S)-Remoxipride TARGET | REMOXIPRIDE | marketed | remoxipride | D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A | 1990-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (remoxipride class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- (S)-Remoxipride CI watch — RSS
- (S)-Remoxipride CI watch — Atom
- (S)-Remoxipride CI watch — JSON
- (S)-Remoxipride alone — RSS
- Whole remoxipride class — RSS
Cite this brief
Drug Landscape (2026). (S)-Remoxipride — Competitive Intelligence Brief. https://druglandscape.com/ci/remoxipride. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab